Leading the Science

In Inflammation Drug Discovery

Targeting Chronic Inflammation

to Treat Neurodegeneration and Inflammatory Diseases by Inhibiting the Activity of the NLRP3 Inflammasome

 

 

 

 

 

 

 

 

At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.

In The News

We Are Experienced in Drug Discovery for Oncology and Neurodegeneration

Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer’s disease, and other neurodegenerative disorders, and we leverage these experiences to identify novel targets to treat these diseases.

Meet the Team

Halia Pipeline

NEK7
INHIBITORS

LRRK2
INHIBITORS

Discovery

IND

Enabling

Phase 1

Phase 2

Phase 3
  • Oral Systemic Multiple Indications 86% 86%
  • 86% 86%
  • Ophthalmology 40% 40%
  • Gastroenterology 40% 40%
  • Neuroinflammation 34% 34%
  • Dermatology 20% 20%
  • Intervertebral Disc Disease 20% 20%
  • Alzheimer's Disease 41.5% 41.5%
  • Parkinson's Disease 27% 27%

HT-6184      Lower-Risk Myelodysplastic Syndromes (LR-MDS) (Clinical Trial CTRI/2023/11/059758)
HT-6184      Post-Procedure Diagnostic Biomarkers of Inflammation and Pain (Clinical Trial NCT06241742)

HT-6184
HT-6258
HT-6283
HT-6515
HT-6153
HT-4253
HT-4403

MDS
Inflammatory Pain

 

 

IND 2024

Halia Pipeline

Halia Therapeutics Pipeline

Contact Us

Corporate Headquarters

3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States

info@haliatx.com |  +1 (385) 355-4315